Compare

EoCene Ltd. vs Genelux Corp vs Marker Therapeutics, Inc. vs Lftd Partners Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearEoCene Ltd.
EOCN
Genelux Corp
GNLX
Marker Therapeutics, Inc.
MRKR
Lftd Partners Inc.
LIFD
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenuen/a$8.0K$3.55M$36.92M
Revenue growth (YoY)n/a0.0%-46.2%-1.1%
Gross marginn/an/an/a34.2%
Operating marginn/an/m-363.5%2.5%
Net marginn/an/m-343.0%-67.3%
Net income$6.90M-$32.15M-$12.16M-$24.86M
EPS (Diluted)$2.39-$0.86-$0.79-$1.68
Operating cash flow-$6.32M-$25.27M-$12.01M$1.32M
Free cash flown/a-$26.37Mn/a$1.20M
Cash & equivalents$3.98M$5.33M$16.07M$1.77M
Total assets$18.63M$19.03M$19.07M$19.27M
Total liabilitiesn/a$7.48M$2.27M$6.64M
Shareholders' equity$15.78M$11.54M$16.80M$12.63M
Return on year-end equity43.7%-278.5%-72.4%-196.8%
Shares outstanding6.58M38.14M16.70M14.82M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearEoCene Ltd.Genelux CorpMarker Therapeutics, Inc.Lftd Partners Inc.
Latest$0
Ended 2020-12-31
$8.0K
Ended 2025-12-31
$3.55M
Ended 2025-12-31
$36.92M
Ended 2025-12-31
1 year earlier$0
Ended 2019-12-31
$8.0K
Ended 2024-12-31
$6.59M
Ended 2024-12-31
$37.33M
Ended 2024-12-31
2 years earlier$2.04M
Ended 2018-12-31
$170.0K
Ended 2023-12-31
$3.31M
Ended 2023-12-31
$51.61M
Ended 2023-12-31
3 years earlier$1.08M
Ended 2017-12-31
$11.07M
Ended 2022-12-31
$3.51M
Ended 2022-12-31
$57.42M
Ended 2022-12-31
4 years earlier$467.0K
Ended 2016-12-31
n/a$1.24M
Ended 2021-12-31
$31.66M
Ended 2021-12-31